Phosphodiesterase 5 inhibitors: Current status and potential applications

Research output: Contribution to journalReview article

219 Citations (Scopus)

Abstract

Phosphodiesterase enzymes convert cyclic GMP and cyclic AMP to the corresponding nucleotide monophosphates. Phosphodiesterase 5 (PDE5) inhibition is now a widely accepted and efficacious therapeutic option for the treatment of erectile dysfunction in men, as a result of extensive clinical experience with sildenafil and other new PDE5 inhibitors. Research in the field continues at a substantial level to identify new, selective PDE5 inhibitors and to investigate their usefulness and activity in other areas. This review summarizes recent clinical trials with PDE5 inhibitors, advances in medicinal chemistry, and other activities and potential applications of this class of compounds.

Original languageEnglish
Pages (from-to)674-682
Number of pages9
JournalNature Reviews Drug Discovery
Volume1
Issue number9
DOIs
StatePublished - 1 Sep 2002

Fingerprint

Phosphodiesterase 5 Inhibitors
Type 5 Cyclic Nucleotide Phosphodiesterases
Pharmaceutical Chemistry
Phosphoric Diester Hydrolases
Erectile Dysfunction
Cyclic AMP
Nucleotides
Clinical Trials
Enzymes
Therapeutics
Research

Cite this

@article{f00f0fdee6d946d5bd45f2e6a0e4e982,
title = "Phosphodiesterase 5 inhibitors: Current status and potential applications",
abstract = "Phosphodiesterase enzymes convert cyclic GMP and cyclic AMP to the corresponding nucleotide monophosphates. Phosphodiesterase 5 (PDE5) inhibition is now a widely accepted and efficacious therapeutic option for the treatment of erectile dysfunction in men, as a result of extensive clinical experience with sildenafil and other new PDE5 inhibitors. Research in the field continues at a substantial level to identify new, selective PDE5 inhibitors and to investigate their usefulness and activity in other areas. This review summarizes recent clinical trials with PDE5 inhibitors, advances in medicinal chemistry, and other activities and potential applications of this class of compounds.",
author = "David Rotella",
year = "2002",
month = "9",
day = "1",
doi = "10.1038/nrd893",
language = "English",
volume = "1",
pages = "674--682",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "9",

}

Phosphodiesterase 5 inhibitors : Current status and potential applications. / Rotella, David.

In: Nature Reviews Drug Discovery, Vol. 1, No. 9, 01.09.2002, p. 674-682.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Phosphodiesterase 5 inhibitors

T2 - Current status and potential applications

AU - Rotella, David

PY - 2002/9/1

Y1 - 2002/9/1

N2 - Phosphodiesterase enzymes convert cyclic GMP and cyclic AMP to the corresponding nucleotide monophosphates. Phosphodiesterase 5 (PDE5) inhibition is now a widely accepted and efficacious therapeutic option for the treatment of erectile dysfunction in men, as a result of extensive clinical experience with sildenafil and other new PDE5 inhibitors. Research in the field continues at a substantial level to identify new, selective PDE5 inhibitors and to investigate their usefulness and activity in other areas. This review summarizes recent clinical trials with PDE5 inhibitors, advances in medicinal chemistry, and other activities and potential applications of this class of compounds.

AB - Phosphodiesterase enzymes convert cyclic GMP and cyclic AMP to the corresponding nucleotide monophosphates. Phosphodiesterase 5 (PDE5) inhibition is now a widely accepted and efficacious therapeutic option for the treatment of erectile dysfunction in men, as a result of extensive clinical experience with sildenafil and other new PDE5 inhibitors. Research in the field continues at a substantial level to identify new, selective PDE5 inhibitors and to investigate their usefulness and activity in other areas. This review summarizes recent clinical trials with PDE5 inhibitors, advances in medicinal chemistry, and other activities and potential applications of this class of compounds.

UR - http://www.scopus.com/inward/record.url?scp=0036717930&partnerID=8YFLogxK

U2 - 10.1038/nrd893

DO - 10.1038/nrd893

M3 - Review article

C2 - 12209148

AN - SCOPUS:0036717930

VL - 1

SP - 674

EP - 682

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 9

ER -